Exact Mass: 660.2801776000001
Exact Mass Matches: 660.2801776000001
Found 196 metabolites which its exact mass value is equals to given mass value 660.2801776000001,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Coproporphyrinogen III
Coproporphyrinogen III is a porphyrin metabolite arising from heme synthesis. Porphyrins are pigments found in both animal and plant life. Coproporphyrinogen III is a tetrapyrrole dead-end product resulting from the spontaneous oxidation of the methylene bridges of coproporphyrinogen arising from heme synthesis. It is secreted in feces and urine. Coproporphyrinogen III is biosynthesized from the tetrapyrrole hydroxymethylbilane, which is converted by the action of uroporphyrinogen III synthase to uroporphyrinogen III. Uroporphyrinogen III is subsequently converted into coproporphyrinogen III through a series of four decarboxylations. Increased levels of coproporphyrinogens can indicate congenital erythropoietic porphyria or sideroblastic anemia, which are inherited disorders. Porphyria is a pathological state characterized by abnormalities of porphyrin metabolism and results in the excretion of large quantities of porphyrins in the urine and in extreme sensitivity to light. A large number of factors are capable of increasing porphyrin excretion, owing to different and multiple causes and etiologies: (1) the main site of the chronic hepatic porphyria disease process concentrates on the liver, (2) a functional and morphologic liver injury is almost regularly associated with this chronic porphyria, and (3) the toxic form due to occupational and environmental exposure takes mainly a subclinical course. Hepatic factors include disturbance in coproporphyrinogen metabolism, which results from inhibition of coproporphyrinogen oxidase as well as from the rapid loss and diminished utilization of coproporphyrinogen in the hepatocytes. This may also explain why coproporphyrin, its autoxidation product, predominates physiologically in the urine. Decreased biliary excretion of coproporphyrin leading to a compensatory urinary excretion. Therefore, the coproporphyrin ring isomer ratio (1:III) becomes a sensitive index for impaired liver function, intrahepatic cholestasis, and disturbed activity of hepatic uroporphyrinogen decarboxylase. In itself, secondary coproporphyrinuria is not associated with porphyria symptoms of a hepatologic-gastroenterologic, neurologic, or dermatologic order, even though coproporphyrinuria can occur with such symptoms (PMID: 3327428). Under certain conditions, coproporphyrinogen III can act as a phototoxin, a neurotoxin, and a metabotoxin. A phototoxin leads to cell damage upon exposure to light. A neurotoxin causes damage to nerve cells and nerve tissues. A metabotoxin is an endogenously produced metabolite that causes adverse health effects at chronically high levels. Chronically high levels of porphyrins are associated with porphyrias such as porphyria variegate, acute intermittent porphyria, hereditary coproporphyria (HCP), congenital erythropoietic porphyria, and sideroblastic anemia. In particular, coproporphyrinogen III is accumulated and excreted excessively in the feces in acute intermittent porphyria, protoporphyria, and variegate porphyria. There are several types of porphyrias (most are inherited). Hepatic porphyrias are characterized by acute neurological attacks (seizures, psychosis, extreme back and abdominal pain, and an acute polyneuropathy), while the erythropoietic forms present with skin problems (usually a light-sensitive blistering rash and increased hair growth). The neurotoxicity of porphyrins may be due to their selective interactions with tubulin, which disrupt microtubule formation and cause neural malformations (PMID: 3441503). Coproporphyrinogen III oxidase is deficient in hereditary coproporphyria. These persons usually have enhanced excretion even in a subclinical state of the disease.(PubMed ID 14605502 ) [HMDB]. Coproporphyrinogen III is found in many foods, some of which are cucumber, climbing bean, horseradish, and pepper (c. frutescens). COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Coproporphyrinogen I
Coproporphyrinogen I is a porphyrin metabolite arising from heme synthesis. Porphyrins are pigments found in both animal and plant life. Coproporphyrinogen I is a tetrapyrrole dead-end product resulting from the spontaneous oxidation of the methylene bridges of coproporphyrinogen arising from heme synthesis. It is secreted in feces and urine. Coproporphyrinogen I is biosynthesized from the tetrapyrrole hydroxymethylbilane, which is converted by the action of uroporphyrinogen synthase to uroporphyrinogen I. Uroporphyrinogen I is subsequently converted into coproporphyrinogen I through a series of four decarboxylations. Increased levels of coproporphyrinogens can indicate congenital erythropoietic porphyria or sideroblastic anemia, which are inherited disorders. Porphyria is a pathological state characterized by abnormalities of porphyrin metabolism and results in the excretion of large quantities of porphyrins in the urine and in extreme sensitivity to light. A large number of factors are capable of increasing porphyrin excretion, owing to different and multiple causes and etiologies: (1) the main site of the chronic hepatic porphyria disease process concentrates on the liver, (2) a functional and morphologic liver injury is almost regularly associated with this chronic porphyria, and (3) the toxic form due to occupational and environmental exposure takes mainly a subclinical course. Hepatic factors include disturbance in coproporphyrinogen metabolism, which results from inhibition of coproporphyrinogen oxidase as well as from the rapid loss and diminished utilization of coproporphyrinogen in the hepatocytes. This may also explain why coproporphyrin, its autoxidation product, predominates physiologically in the urine. Decreased biliary excretion of coproporphyrin leading to a compensatory urinary excretion. Therefore, the coproporphyrin ring isomer ratio becomes a sensitive index for impaired liver function, intrahepatic cholestasis, and disturbed activity of hepatic uroporphyrinogen decarboxylase. In itself, secondary coproporphyrinuria is not associated with porphyria symptoms of a hepatologic-gastroenterologic, neurologic, or dermatologic order, even though coproporphyrinuria can occur with such symptoms (PMID: 3327428). Under certain conditions, coproporphyrinogen I can act as a phototoxin, a neurotoxin, and a metabotoxin. A phototoxin leads to cell damage upon exposure to light. A neurotoxin causes damage to nerve cells and nerve tissues. A metabotoxin is an endogenously produced metabolite that causes adverse health effects at chronically high levels. Chronically high levels of porphyrins are associated with porphyrias such as porphyria variegate, acute intermittent porphyria, hereditary coproporphyria (HCP), congenital erythropoietic porphyria, and sideroblastic anemia. There are several types of porphyrias (most are inherited). Hepatic porphyrias are characterized by acute neurological attacks (seizures, psychosis, extreme back and abdominal pain, and an acute polyneuropathy), while the erythropoietic forms present with skin problems (usually a light-sensitive blistering rash and increased hair growth). The neurotoxicity of porphyrins may be due to their selective interactions with tubulin, which disrupt microtubule formation and cause neural malformations (PMID: 3441503). Coproporphyrinogen I can be found in a number of food items, including cascade huckleberry, hyacinth bean, horseradish tree, and watercress. Formed by Uroporphyrinogen decarboxylase from Uroporphyrinogen I by decarboxylation of 4 acetates. [HMDB]. Coproporphyrinogen I is found in many foods, some of which are alpine sweetvetch, japanese persimmon, komatsuna, and celery leaves.
[(2R,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-sulfooxy-tetrahydropyran-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-3-yl] hexadecanoate
C28H52O15S (660.3026762000001)
Taccalonolide B
Taccalonolide B is a natural product found in Tacca plantaginea and Tacca chantrieri with data available. Taccalonolide B is microtubule stabilizer isolated from Tacca plantaginea, with antitumor activity. Taccalonolide B is effective in vitro against cell lines that overexpress P-glycoprotein (Pgp) and multidrug-resistance protein (MRP7). Taccalonolide B inhibits growth of SK-OV-3 cells with an IC50 of 208 nM[1][2]. Taccalonolide B is microtubule stabilizer isolated from Tacca plantaginea, with antitumor activity. Taccalonolide B is effective in vitro against cell lines that overexpress P-glycoprotein (Pgp) and multidrug-resistance protein (MRP7). Taccalonolide B inhibits growth of SK-OV-3 cells with an IC50 of 208 nM[1][2].
2)-rhamnoside
2''-O-Rhamnosylicariside II is a flavonoid glycoside compound and might be beneficial for improving postmenopausal osteoporosis.
Calyflorenone A
12-O-Deacetyltrichilin H
A limonoid isolated from the ripe fruits of Melia azedarach.
14alpha,15beta-diacetoxy-3beta,7beta-dibenzoyloxy-17-hydroxy-9-oxo-2betaH,13betaH-jatropha-5E,11E-diene|17-hydroxy-euphoscopin C
1alpha,11beta-diacetoxy-4alpha-carbomethoxy-7alpha-hydroxy-12alpha-(2-methylpropanoyloxy)-15-oxohavanensin
12-O-desacetyl-12-O-benzoylpteroidine
C34H41ClO11 (660.2337266000001)
2-O-RHAMNOSYLICARISIDE II
2''-O-Rhamnosylicariside II is a flavonoid glycoside compound and might be beneficial for improving postmenopausal osteoporosis.
3,7-O-diacetyl-5,14-O-dibenzoyl-13,17-oxypremyrsinol
3_,14_-O-diacetoxy-5_-7_-O-dibenzoyloxy-15_-hydroxy-17,13-oxypremyrsinol
3,14-O-diacetyl-5-7-O-dibenzoyl-13,17-oxypremyrsinol
His Arg Trp Tyr
His Arg Tyr Trp
His Trp Arg Tyr
His Trp Tyr Arg
His Tyr Arg Trp
His Tyr Trp Arg
Asn Arg Trp Trp
Asn Trp Arg Trp
Asn Trp Trp Arg
Arg His Trp Tyr
Arg His Tyr Trp
Arg Asn Trp Trp
Arg Trp His Tyr
Arg Trp Asn Trp
Arg Trp Trp Asn
Arg Trp Tyr His
Arg Tyr His Trp
Arg Tyr Trp His
Trp His Arg Tyr
Trp His Tyr Arg
Trp Asn Arg Trp
Trp Asn Trp Arg
Trp Arg His Tyr
Trp Arg Asn Trp
Trp Arg Trp Asn
Trp Arg Tyr His
Trp Trp Asn Arg
Trp Trp Arg Asn
Trp Tyr His Arg
Trp Tyr Arg His
Tyr His Arg Trp
Tyr His Trp Arg
Tyr Arg His Trp
Tyr Arg Trp His
Tyr Trp His Arg
Tyr Trp Arg His
2,7-Bis(9H-fluoren-2-yl)-4,9-diphenylpyrido[2,3-g]quinoline
(-)-1,2-BIS((2R,5R)-2,5-DIETHYLPHOSPHOLANO)BENZENE(CYCLOOCTADIENE)RHODIUM(L)TETRAFLUOROBORATE
C30H48BF4P2Rh (660.2315275999999)
(R)-(+)-2,2-BIS(N-DIPHENYLPHOSPHINOAMINO)-5,5,6,6,7,7,8,8-OCTAHYDRO-1,1-BINAPHTHYL
C44H42N2P2 (660.2823072000001)
5-DMT-2-TBDMS-RU
5'-O-DMT-2'-TBDMS-Uridine is a deoxyribonucleoside used for the oligonucleotide synthesis.
butane-1,4-diol,1,3-diisocyanato-2-methylbenzene,hexanedioic acid,1-isocyanato-4-[(4-isocyanatophenyl)methyl]benzene
(11bR)-2,6-Bis([1,1-biphenyl]-4-yl)-8,9,10,11,12,13,14,15-octahydro-4-hydroxy-4-oxide-dinaphtho[2,1-d:1,2-f][1,3,2]dioxaphosphepin
1,3,3-Trimethyl-2-[(E)-2-{(3E)-2-[(1-phenyl-1H-tetrazol-5-yl)sulf anyl]-3-[(2E)-2-(1,3,3-trimethyl-1,3-dihydro-2H-indol-2-ylidene)e thylidene]-1-cyclohexen-1-yl}vinyl]-3H-indolium chloride
C39H41ClN6S (660.2801776000001)
Metkephamid acetate
C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D018377 - Neurotransmitter Agents > D018847 - Opioid Peptides D018377 - Neurotransmitter Agents > D004745 - Enkephalins
12-Ethyl-71,71-dihydroxy-8-isobutylbacteriochlorophyllide c
(+-)-chartaceone C
A dihydroxyflavanone that is flavanone substituted by hydroxy groups at positions 5 and 7 and 6-carboxy-1-phenylhex-2-en-1-yl groups at positions 6 and 8 respectively. It has been isolated as a racemate from the bark of Cryptocarya chartacea and exhibits inhibitory activity against dengue virus NS5 polymerase.
(+-)-chartaceone F
A dihydroxyflavanone that is flavanone substituted by hydroxy groups at positions 5 and 7 and 6-carboxy-1-phenylhex-1-en-3-yl groups at positions 6 and 8 respectively. It has been isolated as a racemate from the bark of Cryptocarya chartacea and exhibits inhibitory activity against dengue virus NS5 polymerase.
(+-)-chartaceone D
A dihydroxyflavanone that is flavanone substituted by hydroxy groups at positions 5 and 7, 6-carboxy-1-phenylhex-2-en-1-yl group at positions 6 and a 6-carboxy-1-phenylhex-1-en-3-yl group at position 8. It has been isolated as a racemate from the bark of Cryptocarya chartacea and exhibits inhibitory activity against dengue virus NS5 polymerase.
(+-)-chartaceone E
A dihydroxyflavanone that is flavanone substituted by hydroxy groups at positions 5 and 7, a 6-carboxy-1-phenylhex-2-en-1-yl group at position 8 and 6-carboxy-1-phenylhex-2-en-3-yl groups at position 6. It has been isolated as a racemate from the bark of Cryptocarya chartacea and exhibits inhibitory activity against dengue virus NS5 polymerase.
1-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxy-3-methylphenyl)sulfonyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-3-(1-naphthalenyl)urea
alpha-D-glucopyranosyl-(1->3)-6-deoxy-alpha-L-mannopyranosyl-(1->2)-6-deoxy-alpha-L-mannopyranosyl-(1->3)-2-O-acetyl-6-deoxy-alpha-L-mannopyranose
2-{5-[2-tert-butyl-7-(diethylamino)-4H-chromen-4-ylidene]penta-1,3-dien-1-yl}-1-(5-carboxypentyl)-3,3-dimethyl-3H-indolium-5-sulfonate
[1-acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
[1-butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate
coproporphyrinogen III
COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
4,20-bis(acetyloxy)-6-(furan-3-yl)-12,19,21-trihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-16-yl 2-methylpropanoate
6-(furan-3-yl)-15,16-dihydroxy-12-(2-methoxy-2-oxoethyl)-7,11,13,13-tetramethyl-14-[(2-methylpropanoyl)oxy]-4-oxo-5,17-dioxapentacyclo[13.2.1.0¹,¹⁰.0²,⁷.0¹¹,¹⁶]octadecan-18-yl 2-methylpropanoate
(1s,2r,4r,5r,6s,8r,10r,11s,12r,14r,15r,16s,19r,20r,21s)-20,21-bis(acetyloxy)-6-(furan-3-yl)-4,12,19-trihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-16-yl 2-methylpropanoate
(1s,2r,3r,4s,5r,7s,8r,9r,10r,13r,15r)-2-(acetyloxy)-4-formyl-13-(furan-3-yl)-5-hydroxy-9-(2-methoxy-2-oxoethyl)-4,8,10,12-tetramethyl-16-oxatetracyclo[8.6.0.0³,⁸.0¹¹,¹⁵]hexadec-11-en-7-yl (2e)-3-phenylprop-2-enoate
(1s,2s,4r,5s,7s,9s,10r,11s,12s,13s,14r,15r,16s,17s,22s,23s,24r,25r)-13,14-bis(acetyloxy)-4,22,25-trihydroxy-11,15,17,22,23-pentamethyl-3,21-dioxo-8,20-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹¹.0⁷,⁹.0¹⁶,²⁴.0¹⁹,²³]pentacos-18-en-10-yl acetate
2-(acetyloxy)-4-formyl-13-(furan-3-yl)-5-hydroxy-9-(2-methoxy-2-oxoethyl)-4,8,10,12-tetramethyl-16-oxatetracyclo[8.6.0.0³,⁸.0¹¹,¹⁵]hexadec-11-en-7-yl 3-phenylprop-2-enoate
2''-o-rhamnosyl icariside ii
{"Ingredient_id": "HBIN006265","Ingredient_name": "2''-o-rhamnosyl icariside ii","Alias": "NA","Ingredient_formula": "C33H40O14","Ingredient_Smile": "CC1C(C(C(C(O1)OC2C(C(C(OC2OC3=C(OC4=C(C(=CC(=C4C3=O)O)O)CC=C(C)C)C5=CC=C(C=C5)OC)C)O)O)O)O)O","Ingredient_weight": "660.7 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "18726","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "123134743","DrugBank_id": "NA"}
3-deacetyltrichilin h
{"Ingredient_id": "HBIN008414","Ingredient_name": "3-deacetyltrichilin h","Alias": "NA","Ingredient_formula": "C34H44O13","Ingredient_Smile": "NA","Ingredient_weight": "660.714","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "8154","PubChem_id": "NA","DrugBank_id": "NA"}
anhydroicaritin-3-o-alpha-l-rhamnopyranosyl-(1-2)-alpha-l-rhamnopyranoside
{"Ingredient_id": "HBIN016164","Ingredient_name": "anhydroicaritin-3-o-alpha-l-rhamnopyranosyl-(1-2)-alpha-l-rhamnopyranoside","Alias": "NA","Ingredient_formula": "C33H40O14","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "30607","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
anhydroicaritin-3-o-α-l-rhamnopyranosyl-(1→2)-α-l-rhamnopyranoside
{"Ingredient_id": "HBIN016165","Ingredient_name": "anhydroicaritin-3-o-\u03b1-l-rhamnopyranosyl-(1\u21922)-\u03b1-l-rhamnopyranoside","Alias": "NA","Ingredient_formula": "C33H40O14","Ingredient_Smile": "CC1C(C(C(C(O1)OC2C(C(C(OC2OC3=C(OC4=C(C3=O)C(=CC(=C4CC=C(C)C)O)O)C5=CC=C(C=C5)OC)C)O)O)O)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1274","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
5-(4-bromobuta-1,3-dien-1-yl)-1,11-dihydroxy-2,7,12-trimethyl-15-[(3,4,5-trimethoxy-6-methyloxan-2-yl)oxy]-4,17-dioxabicyclo[11.3.1]heptadec-8-en-3-one
2-(4-{5-[1,3-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)propyl]-3-(hydroxymethyl)-7-methoxy-2,3-dihydro-1-benzofuran-2-yl}-2-methoxyphenoxy)-6-(hydroxymethyl)oxane-3,4,5-triol
14,30,32-trihydroxy-12-methoxy-4,8,18,22,26-pentamethyl-3,7,17,21,25-pentaoxatricyclo[26.4.0.0¹⁰,¹⁵]dotriaconta-1(32),10,12,14,28,30-hexaene-2,6,16,20,24-pentone
(1r,18s,19s,20s)-19-ethenyl-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-18-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-17-oxa-3,13-diazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,15-pentaen-14-one
4-{[2-(2,4-dihydroxyphenyl)-7-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-5,6-dihydroxy-1-benzofuran-3-yl]methyl}-8,17-dioxatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁶]heptadeca-1(10),2(7),3,5,11,13,15-heptaene-5,14-diol
(2z)-4-[(1s,2s,8r,15s,16s,17s,19r)-12-hydroxy-16-methoxy-8,21,21-trimethyl-5-(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4,6(11),9,12-tetraen-19-yl]-2-methylbut-2-enoic acid
(1r,4r,9r)-9-[(1s,4s,7s,8s,9s)-7,8-dihydroxy-4-(hydroxymethyl)-5-methyl-3,6-dioxo-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-10,12,14-trien-9-yl]-4-isopropyl-5-methyl-4-(methylsulfanyl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-7,10,12,14-tetraene-3,6-dione
(2r,3s,3as,6r,12r,13r,13ar)-13,13a-bis(acetyloxy)-3-(benzoyloxy)-5-(hydroxymethyl)-2,9,9,12-tetramethyl-8-oxo-1h,2h,3h,3ah,6h,7h,12h,13h-cyclopenta[12]annulen-6-yl benzoate
methyl (1s,2r,4s,6s,7r,8r,9r,10r,11s,12s,14r,15s,16r,18r)-8,18-bis(acetyloxy)-6-(furan-3-yl)-12,14-dihydroxy-1,7,11,15-tetramethyl-9-[(2-methylpropanoyl)oxy]-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadecane-15-carboxylate
(2s,3r,4s,5r,6r)-2-{4-[(2r,3s)-5-[(1r,2s)-1,3-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)propyl]-3-(hydroxymethyl)-7-methoxy-2,3-dihydro-1-benzofuran-2-yl]-2-methoxyphenoxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(8r,9s,10s,11s)-9-hydroxy-3,4,5,19-tetramethoxy-9,10-dimethyl-11-{[(2e)-3-phenylprop-2-enoyl]oxy}-15,17-dioxatetracyclo[10.7.0.0²,⁷.0¹⁴,¹⁸]nonadeca-1(12),2,4,6,13,18-hexaen-8-yl (2e)-2-methylbut-2-enoate
3-{[(2s,3s,4r,5r,6s)-4,5-dihydroxy-6-methyl-3-{[(2s,3s,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)chromen-4-one
20,21-bis(acetyloxy)-6-(furan-3-yl)-4,12,19-trihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-16-yl 2-methylpropanoate
(1r,2s,4s,5s,6r,8s,10r,11r,12s,14s,15s,16r,19s,20s,21r)-20,21-bis(acetyloxy)-6-(furan-3-yl)-4,12,19-trihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-16-yl 2-methylpropanoate
(2e)-3-[(1s,3s,6r)-3-({[(2e)-3-[(1s,2s,3s,6r)-3-(chloromethyl)-3-hydroxy-6-isopropyl-2-(methoxycarbonyl)cyclohexyl]-2-(hydroxymethyl)prop-2-enoyl]oxy}methyl)-3-hydroxy-6-isopropyl-2-(methoxycarbonyl)cyclohexyl]-2-(hydroxymethyl)prop-2-enoic acid
C32H49ClO12 (660.2912384000001)
(2s,3r,4s,5r,6r)-2-{[(1r,18s,19r,20s)-19-ethenyl-14-oxo-17-oxa-3,13-diazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,15-pentaen-18-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl (2e)-3-(3,4-dihydroxyphenyl)prop-2-enoate
(2s,3r,4s,5s,6r)-2-{4-[(2r,3s)-5-[(1s,2r)-1,3-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)propyl]-3-(hydroxymethyl)-7-methoxy-2,3-dihydro-1-benzofuran-2-yl]-2-methoxyphenoxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(1s,2r,3r,5s,7s,9s,10r,11r,12s,13r,14r,15r,16s,17s,22s,23s,24s,25r)-14,25-bis(acetyloxy)-3,13,22-trihydroxy-11,15,17,22,23-pentamethyl-4,21-dioxo-8,20-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹¹.0⁷,⁹.0¹⁶,²⁴.0¹⁹,²³]pentacos-18-en-10-yl acetate
13,13a-bis(acetyloxy)-3-(benzoyloxy)-5-(hydroxymethyl)-2,9,9,12-tetramethyl-8-oxo-1h,2h,3h,3ah,6h,7h,12h,13h-cyclopenta[12]annulen-6-yl benzoate
13,14-bis(acetyloxy)-4,22,25-trihydroxy-11,15,17,22,23-pentamethyl-3,21-dioxo-8,20-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹¹.0⁷,⁹.0¹⁶,²⁴.0¹⁹,²³]pentacos-18-en-10-yl acetate
[9a,11a-dimethyl-1-(6-methylheptan-2-yl)-7,8-bis(sulfooxy)-tetradecahydro-1h-cyclopenta[a]phenanthren-5-yl]oxidanesulfonic acid
[(1r,3as,3bs,5s,5as,7s,8s,9ar,9bs,11ar)-9a,11a-dimethyl-1-[(2r)-6-methylheptan-2-yl]-7,8-bis(sulfooxy)-tetradecahydro-1h-cyclopenta[a]phenanthren-5-yl]oxidanesulfonic acid
10-[(acetyloxy)methyl]-2,4,10,11,12-pentahydroxy-2,6,14,14-tetramethyl-9-[(2-methylbut-2-enoyl)oxy]-3,13-dioxotricyclo[10.3.0.0⁴,⁸]pentadecan-7-yl benzoate
3-{[(2s,3r,4r,5r,6s)-4,5-dihydroxy-6-methyl-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)chromen-4-one
3-{[(2s,3s,4s,5r,6s)-4,5-dihydroxy-6-methyl-3-{[(2s,3s,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)chromen-4-one
2-({19-ethenyl-14-oxo-17-oxa-3,13-diazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,15-pentaen-18-yl}oxy)-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl 3-(3,4-dihydroxyphenyl)prop-2-enoate
3-[(11s,17s,20s,23s)-2,9,18,21-tetrahydroxy-11-isopropyl-20-(2-methylpropyl)-12-oxo-6,25-dithia-3,10,13,19,22,27,28-heptaazatetracyclo[22.2.1.1⁵,⁸.0¹³,¹⁷]octacosa-1(26),2,5(28),7,9,18,21,24(27)-octaen-23-yl]propanimidic acid
C29H40N8O6S2 (660.2512100000001)
(1r,2r,5r,7r,8z,11r,12s,13s,15s)-5-[(1e,3e)-4-bromobuta-1,3-dien-1-yl]-1,11-dihydroxy-2,7,12-trimethyl-15-{[(2s,3s,4r,5r,6r)-3,4,5-trimethoxy-6-methyloxan-2-yl]oxy}-4,17-dioxabicyclo[11.3.1]heptadec-8-en-3-one
(1s,2r,4r,5s,6r,8s,10r,11s,12s,14r,15r,16s,19r,20s,21r)-4,20-bis(acetyloxy)-6-(furan-3-yl)-12,19,21-trihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-16-yl 2-methylpropanoate
(1s,2r,3r,7s,9r,11s,12s,15r,16s,17s,22s,23s,24s,25r)-14,25-bis(acetyloxy)-5,10,22-trihydroxy-11,15,17,22,23-pentamethyl-4,21-dioxo-8,20-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹¹.0⁷,⁹.0¹⁶,²⁴.0¹⁹,²³]pentacos-18-en-3-yl acetate
(2r,5s,7r,10r,11r,15r,17s)-2,7,10,11,15,20,21-heptamethoxy-5,17-diphenyl-4,12,18-trioxapentacyclo[11.8.0.0²,¹¹.0³,⁸.0¹⁴,¹⁹]henicosa-1(21),3(8),13,19-tetraen-9-one
(1r,18s,19r,20s)-19-ethenyl-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-18-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-17-oxa-3,13-diazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,15-pentaen-14-one
methyl 2-[4,5,16-tris(acetyloxy)-13-(furan-3-yl)-11-hydroxy-6,6,8,12-tetramethyl-17-methylidene-9,15-dioxo-2,14-dioxatetracyclo[8.6.1.0¹,¹².0³,⁸]heptadecan-7-yl]acetate
methyl 9,10-bis(acetyloxy)-1-(furan-3-yl)-4,7-dihydroxy-3b,6,9a,11a-tetramethyl-11-[(2-methylpropanoyl)oxy]-3-oxo-dodecahydrocyclopenta[a]phenanthrene-6-carboxylate
(1s,2s,3r,5s,7s,9s,10r,11r,12s,13s,14r,15r,16s,17s,22s,23s,24r,25r)-13,14-bis(acetyloxy)-3,22,25-trihydroxy-11,15,17,22,23-pentamethyl-4,21-dioxo-8,20-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹¹.0⁷,⁹.0¹⁶,²⁴.0¹⁹,²³]pentacos-18-en-10-yl acetate
methyl 8,18-bis(acetyloxy)-6-(furan-3-yl)-12,14-dihydroxy-1,7,11,15-tetramethyl-9-[(2-methylpropanoyl)oxy]-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadecane-15-carboxylate
(1r,4s,9r)-9-[(1s,4s,7s,8s,9s)-7,8-dihydroxy-4-(hydroxymethyl)-5-methyl-3,6-dioxo-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-10,12,14-trien-9-yl]-4-isopropyl-5-methyl-4-(methylsulfanyl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-7,10,12,14-tetraene-3,6-dione
methyl (1s,3ar,3br,4r,5ar,6s,7r,9s,9as,9bs,10r,11r,11as)-9,10-bis(acetyloxy)-1-(furan-3-yl)-4,7-dihydroxy-3b,6,9a,11a-tetramethyl-11-[(2-methylpropanoyl)oxy]-3-oxo-dodecahydrocyclopenta[a]phenanthrene-6-carboxylate
3-[2,9,18,21-tetrahydroxy-11-isopropyl-20-(2-methylpropyl)-12-oxo-6,25-dithia-3,10,13,19,22,27,28-heptaazatetracyclo[22.2.1.1⁵,⁸.0¹³,¹⁷]octacosa-1(26),2,5(28),7,9,18,21,24(27)-octaen-23-yl]propanimidic acid
C29H40N8O6S2 (660.2512100000001)